TACE 联合射频消融术与卡瑞利珠单抗治疗原发性 肝癌的临床疗效及预后研究Δ.

OBJECTIVE: To probe into the clinical efficacy and prognosis of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation and camrelizumab in the treatment of primary liver cancer. METHODS: Retrospective analysis was performed on clinical data of 102 patients with primary liver cancer in Hengshui the Third People’s Hospital from Mar. 2017 and Aug. 2019, according to different therapeutic regimens, 51 patients received TACE combined with radiofrequency ablation and camrelizumab were enrolled into group A, and another 51 patients received TACE combined with radiofrequency ablation were enrolled into group B. The clinical efficacy, tumor markers, T lymphocyte, liver function, incidence of complications and survival were compared between two groups. RESULTS: The clinical effective rate of group A was 90. 20% (46 / 51), which was higher than that of group B ( 74. 51%, 38 / 51), with statistically significant difference ( P < 0. 05). The serum alpha fetal protein, carcinoma antigen 199 and carcino-embryonic antigen levels of group A were lower than those of group B after treatment, with statistically significant differences (P<0. 05). The peripheral blood CD4+ and CD4+ / CD8+ levels of group A were higher, the peripheral blood CD4+ CD25+ FOXP3+ Treg and CD8+ levels were lower in group A than those in group B after treatment, with statistically significant differences (P<0. 05). There were no statistical significance in differences in liver function indicators (aspartate transaminase, alanine aminotransferase and total bilirubin) between two groups after treatment (P>0. 05). The incidences of reactive capillary hyperplasia and thrombocytopenia of group A were higher than those of group B, with statistically significant differences (P< 0. 05). There were no statistical significance in differences in 2-year progression-free survival and total survival between two groups ( P > 0. 05). CONCLUSIONS: The application of camrelizumab on the basis of TACE combined with radiofrequency ablation can effective inhibit the expression of tumor markers, promote immune function reconstruction and improve clinical efficacy, however, it also increases the patient’s risk of complications to some extent. [ABSTRACT FROM AUTHOR]